Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
- Author:
Seiji MABUCHI
1
;
Toru SUGIYAMA
;
Tadashi KIMURA
Author Information
- Publication Type:Review
- Keywords: Adenocarcinoma, Clear Cell; Antineoplastic Agents; ARID1A; Carcinogenesis; Interleukin-6; Salvage Therapy
- MeSH: Adenocarcinoma, Clear Cell/drug therapy/*etiology/metabolism; Antineoplastic Agents/therapeutic use; Female; Forecasting; Humans; Neoplasm Recurrence, Local/prevention & control; Ovarian Neoplasms/drug therapy/*etiology/metabolism
- From:Journal of Gynecologic Oncology 2016;27(3):e31-
- CountryRepublic of Korea
- Language:English
- Abstract: Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to chemotherapeutic agents and to be associated with a worse prognosis than the more common serous adenocarcinoma or endometrioid adenocarcinoma. To improve the survival of patients with ovarian CCC, the deeper understanding of the mechanism of CCC carcinogenesis as well as the efforts to develop novel treatment strategies in the setting of both front-line treatment and salvage treatment for recurrent disease are needed. In this presentation, we first summarize the mechanism responsible for carcinogenesis. Then, we highlight the promising therapeutic targets in ovarian CCC and provide information on the novel agents which inhibit these molecular targets. Moreover, we discuss on the cytotoxic anti-cancer agents that can be best combined with targeted agents in the treatment of ovarian CCC.
